Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HCW-9218 by HCW Biologics for Rectal Cancer: Likelihood of Approval
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Rectal Cancer. According to GlobalData, Phase...
HCW-9218 by HCW Biologics for Liver Cancer: Likelihood of Approval
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Liver Cancer. According to GlobalData, Phase...
HCW-9218 by HCW Biologics for Solid Tumor: Likelihood of Approval
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
HCW-9218 by HCW Biologics for Ovarian Cancer: Likelihood of Approval
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
HCW-9218 by HCW Biologics for Solid Tumor: Likelihood of Approval
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
HCW-9218 by HCW Biologics for Ovarian Cancer: Likelihood of Approval
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of HCW Biologics's HCW-9218?
HCW-9218 is a fusion protein commercialized by HCW Biologics, with a leading Phase II program in Metastatic Pancreatic Cancer. According...